254 related articles for article (PubMed ID: 33658498)
1. Somatic mutations and single-cell transcriptomes reveal the root of malignant rhabdoid tumours.
Custers L; Khabirova E; Coorens THH; Oliver TRW; Calandrini C; Young MD; Vieira Braga FA; Ellis P; Mamanova L; Segers H; Maat A; Kool M; Hoving EW; van den Heuvel-Eibrink MM; Nicholson J; Straathof K; Hook L; de Krijger RR; Trayers C; Allinson K; Behjati S; Drost J
Nat Commun; 2021 Mar; 12(1):1407. PubMed ID: 33658498
[TBL] [Abstract][Full Text] [Related]
2. SMARCB1 loss activates patient-specific distal oncogenic enhancers in malignant rhabdoid tumors.
Liu NQ; Paassen I; Custers L; Zeller P; Teunissen H; Ayyildiz D; He J; Buhl JL; Hoving EW; van Oudenaarden A; de Wit E; Drost J
Nat Commun; 2023 Dec; 14(1):7762. PubMed ID: 38040699
[TBL] [Abstract][Full Text] [Related]
3. A dynamic mutational landscape associated with an inter-regionally diverse immune response in malignant rhabdoid tumour.
Yasui H; Valind A; Karlsson J; Pietras C; Jansson C; Wille J; Romerius P; Backman T; Gisselsson D
J Pathol; 2020 Sep; 252(1):22-28. PubMed ID: 32542645
[TBL] [Abstract][Full Text] [Related]
4. Novel Two MRT Cell Lines Established from Multiple Sites of a Synchronous MRT Patient.
Kuwahara Y; Iehara T; Ichise E; Katsumi Y; Ouchi K; Tsuchiya K; Miyachi M; Konishi E; Sasajima H; Nakamura S; Fumino S; Tajiri T; Johann PD; FrÜhwald MC; Yoshida T; Okuda T; Hosoi H
Anticancer Res; 2020 Nov; 40(11):6159-6170. PubMed ID: 33109553
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide approach to identify second gene targets for malignant rhabdoid tumors using high-density oligonucleotide microarrays.
Takita J; Chen Y; Kato M; Ohki K; Sato Y; Ohta S; Sugita K; Nishimura R; Hoshino N; Seki M; Sanada M; Oka A; Hayashi Y; Ogawa S
Cancer Sci; 2014 Mar; 105(3):258-64. PubMed ID: 24418192
[TBL] [Abstract][Full Text] [Related]
6. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM
Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442
[TBL] [Abstract][Full Text] [Related]
7. CD146 is a novel marker for highly tumorigenic cells and a potential therapeutic target in malignant rhabdoid tumor.
Nodomi S; Umeda K; Saida S; Kinehara T; Hamabata T; Daifu T; Kato I; Hiramatsu H; Watanabe KI; Kuwahara Y; Iehara T; Adachi S; Konishi E; Nakahata T; Hosoi H; Heike T
Oncogene; 2016 Oct; 35(40):5317-5327. PubMed ID: 27041577
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor 2 axis supports the serum-independent growth of malignant rhabdoid tumor and is activated by microenvironment stress.
Li T; Wang J; Liu P; Chi J; Yan H; Lei L; Li Z; Yang B; Wang X
Oncotarget; 2017 Jul; 8(29):47269-47283. PubMed ID: 28521298
[TBL] [Abstract][Full Text] [Related]
9. Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development.
Vitte J; Gao F; Coppola G; Judkins AR; Giovannini M
Nat Commun; 2017 Aug; 8(1):300. PubMed ID: 28824165
[TBL] [Abstract][Full Text] [Related]
10. SMARCB1-deficient Tumors of Childhood: A Practical Guide.
Pawel BR
Pediatr Dev Pathol; 2018; 21(1):6-28. PubMed ID: 29280680
[TBL] [Abstract][Full Text] [Related]
11. Translational genomics of malignant rhabdoid tumours: Current impact and future possibilities.
Finetti MA; Grabovska Y; Bailey S; Williamson D
Semin Cancer Biol; 2020 Apr; 61():30-41. PubMed ID: 31923457
[TBL] [Abstract][Full Text] [Related]
12. Familial occurrence of schwannomas and malignant rhabdoid tumour associated with a duplication in SMARCB1.
Swensen JJ; Keyser J; Coffin CM; Biegel JA; Viskochil DH; Williams MS
J Med Genet; 2009 Jan; 46(1):68-72. PubMed ID: 19124645
[TBL] [Abstract][Full Text] [Related]
13. Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells.
Darr J; Klochendler A; Isaac S; Geiger T; Eden A
Mol Cancer; 2015 Sep; 14():167. PubMed ID: 26370283
[TBL] [Abstract][Full Text] [Related]
14. Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors.
Muscat A; Popovski D; Jayasekara WS; Rossello FJ; Ferguson M; Marini KD; Alamgeer M; Algar EM; Downie P; Watkins DN; Cain JE; Ashley DM
Clin Cancer Res; 2016 Jul; 22(14):3560-70. PubMed ID: 26920892
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of SMARCB1 constitutional abnormalities including mosaicism in malignant rhabdoid tumors.
Shirai R; Osumi T; Terashima K; Kiyotani C; Uchiyama M; Tsujimoto S; Yoshida M; Yoshida K; Uchiyama T; Tomizawa D; Shioda Y; Sekiguchi M; Watanabe K; Keino D; Ueno-Yokohata H; Ohki K; Takita J; Ito S; Deguchi T; Kiyokawa N; Ogiwara H; Hishiki T; Ogawa S; Okita H; Matsumoto K; Yoshioka T; Kato M
Eur J Hum Genet; 2020 Aug; 28(8):1124-1128. PubMed ID: 32218533
[TBL] [Abstract][Full Text] [Related]
16. Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases.
Holdhof D; Johann PD; Spohn M; Bockmayr M; Safaei S; Joshi P; Masliah-Planchon J; Ho B; Andrianteranagna M; Bourdeaut F; Huang A; Kool M; Upadhyaya SA; Bendel AE; Indenbirken D; Foulkes WD; Bush JW; Creytens D; Kordes U; Frühwald MC; Hasselblatt M; Schüller U
Acta Neuropathol; 2021 Feb; 141(2):291-301. PubMed ID: 33331994
[TBL] [Abstract][Full Text] [Related]
17. SMARCB1 loss interacts with neuronal differentiation state to block maturation and impact cell stability.
Parisian AD; Koga T; Miki S; Johann PD; Kool M; Crawford JR; Furnari FB
Genes Dev; 2020 Oct; 34(19-20):1316-1329. PubMed ID: 32912900
[TBL] [Abstract][Full Text] [Related]
18. Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways.
Chun HE; Lim EL; Heravi-Moussavi A; Saberi S; Mungall KL; Bilenky M; Carles A; Tse K; Shlafman I; Zhu K; Qian JQ; Palmquist DL; He A; Long W; Goya R; Ng M; LeBlanc VG; Pleasance E; Thiessen N; Wong T; Chuah E; Zhao YJ; Schein JE; Gerhard DS; Taylor MD; Mungall AJ; Moore RA; Ma Y; Jones SJM; Perlman EJ; Hirst M; Marra MA
Cancer Cell; 2016 Mar; 29(3):394-406. PubMed ID: 26977886
[TBL] [Abstract][Full Text] [Related]
19. Malignant rhabdoid tumor shows a unique neural differentiation as distinct from neuroblastoma.
Higashino K; Narita T; Taga T; Ohta S; Takeuchi Y
Cancer Sci; 2003 Jan; 94(1):37-42. PubMed ID: 12708472
[TBL] [Abstract][Full Text] [Related]
20. SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development.
Wei D; Goldfarb D; Song S; Cannon C; Yan F; Sakellariou-Thompson D; Emanuele M; Major MB; Weissman BE; Kuwahara Y
Mol Cancer Res; 2014 Nov; 12(11):1574-85. PubMed ID: 25009291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
